By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Concert Pharmaceuticals, Inc. 

99 Hayden Avenue
Suite 500
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-860-0045 Fax: n/a



Start Up

Company News
Filings Reveal Concert Pharma (CNCE) Spurned $250 Million Buyout Offer From Vertex (VRTX) in November 2016 3/26/2017 8:36:39 PM
Vertex (VRTX) To Acquire CTP-656 From Concert Pharma (CNCE) For The Treatment Of Cystic Fibrosis 3/6/2017 7:01:46 AM
Concert Pharma (CNCE) Presents CTP-543 Phase I Results At American Academy of Dermatology Annual Meeting 3/6/2017 6:53:10 AM
Concert Pharma (CNCE) Reports Year Ended 2016 Financial Results 3/6/2017 6:18:17 AM
Vertex (VRTX) Inks Deal Worth $250 Million for Concert Pharma (CNCE)'s Cystic Fibrosis Drug 3/6/2017 5:39:47 AM
Concert Pharmaceuticals, Inc. (CNCE) To Report Full Year 2016 Results On March 6, 2017, And Present At Upcoming Investor Conferences 3/2/2017 6:22:28 AM
Concert Pharmaceuticals, Inc. (CNCE) Release: Biopharma Receives FDA Orphan Drug Designation For CTP-656 For The Treatment Of Cystic Fibrosis 1/20/2017 7:50:57 AM
Concert Pharmaceuticals, Inc. (CNCE) Release: Company Provides Further Details On CTP-656 Development In U.S. And Europe 1/17/2017 7:57:43 AM
Concert Pharmaceuticals, Inc. (CNCE) Initiates Phase 2 Clinical Trial Evaluating CTP-656 For The Treatment Of Cystic Fibrosis 12/21/2016 12:45:20 PM
Concert Pharmaceuticals, Inc. (CNCE) Announces CTP-543 Positive Top-Line Phase 1 Results 12/14/2016 9:31:07 AM